Tirzepatide and semaglutide

Booming demand for the latest generation of hormone-mimicking weight loss and diabetes drugs has elevated Novo Nordisk and its American rival Eli Lilly into the ranks of the world’s most valuable companies. Alongside Lilly, which sells the drug #tirzepatide as branded diabetes and weight loss medications Mounjaro and Zepbound, Novo enjoys a practical duopoly over the vanguard of a class of drugs called GLP-1 agonists that help regulate blood sugar and appetite. The drugs can be used to help manage diabetes and have been shown to induce a degree of weight loss previously unattainable without surgery. A host of other benefits are also emerging, notably improving #hearthealth, for which Novo has already secured a label expansion for, and there are signs GLP-1s may also be used to help treat or prevent an array of conditions including #sleepapnea, an array of cancers, #addiction, Parkinson’s, dementia and kidney disease. But Novo and Lilly’s explosive growth has slowed dramatically in recent weeks as #drugshortages in the U.S. and efforts to move into new markets weigh on sales forecasts.